JP2013500976A5 - - Google Patents

Download PDF

Info

Publication number
JP2013500976A5
JP2013500976A5 JP2012523006A JP2012523006A JP2013500976A5 JP 2013500976 A5 JP2013500976 A5 JP 2013500976A5 JP 2012523006 A JP2012523006 A JP 2012523006A JP 2012523006 A JP2012523006 A JP 2012523006A JP 2013500976 A5 JP2013500976 A5 JP 2013500976A5
Authority
JP
Japan
Prior art keywords
glucocerebrosidase
antibody
mixture
labeled
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012523006A
Other languages
English (en)
Japanese (ja)
Other versions
JP5815521B2 (ja
JP2013500976A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/043586 external-priority patent/WO2011017177A1/en
Publication of JP2013500976A publication Critical patent/JP2013500976A/ja
Publication of JP2013500976A5 publication Critical patent/JP2013500976A5/ja
Application granted granted Critical
Publication of JP5815521B2 publication Critical patent/JP5815521B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012523006A 2009-07-28 2010-07-28 ゴーシェ病を治療するための組成物および方法 Active JP5815521B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US22919509P 2009-07-28 2009-07-28
US61/229,195 2009-07-28
US30304410P 2010-02-10 2010-02-10
US61/303,044 2010-02-10
US31751310P 2010-03-25 2010-03-25
US61/317,513 2010-03-25
US33337210P 2010-05-11 2010-05-11
US61/333,372 2010-05-11
US35933810P 2010-06-28 2010-06-28
US61/359,338 2010-06-28
PCT/US2010/043586 WO2011017177A1 (en) 2009-07-28 2010-07-28 Compositions and methods for treating gaucher disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015045704A Division JP6066503B2 (ja) 2009-07-28 2015-03-09 ゴーシェ病を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2013500976A JP2013500976A (ja) 2013-01-10
JP2013500976A5 true JP2013500976A5 (https=) 2013-09-12
JP5815521B2 JP5815521B2 (ja) 2015-11-17

Family

ID=43527246

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012523006A Active JP5815521B2 (ja) 2009-07-28 2010-07-28 ゴーシェ病を治療するための組成物および方法
JP2015045704A Active JP6066503B2 (ja) 2009-07-28 2015-03-09 ゴーシェ病を治療するための組成物および方法
JP2016136753A Active JP6378257B2 (ja) 2009-07-28 2016-07-11 ゴーシェ病を治療するための組成物および方法
JP2018000259A Pending JP2018077246A (ja) 2009-07-28 2018-01-04 ゴーシェ病を治療するための組成物および方法
JP2019194895A Pending JP2020033367A (ja) 2009-07-28 2019-10-28 ゴーシェ病を治療するための組成物および方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015045704A Active JP6066503B2 (ja) 2009-07-28 2015-03-09 ゴーシェ病を治療するための組成物および方法
JP2016136753A Active JP6378257B2 (ja) 2009-07-28 2016-07-11 ゴーシェ病を治療するための組成物および方法
JP2018000259A Pending JP2018077246A (ja) 2009-07-28 2018-01-04 ゴーシェ病を治療するための組成物および方法
JP2019194895A Pending JP2020033367A (ja) 2009-07-28 2019-10-28 ゴーシェ病を治療するための組成物および方法

Country Status (15)

Country Link
US (2) US20110027254A1 (https=)
EP (2) EP2459212B1 (https=)
JP (5) JP5815521B2 (https=)
CN (3) CN102686237B (https=)
AU (3) AU2010281403B2 (https=)
CA (2) CA2768999C (https=)
CO (1) CO6660423A2 (https=)
ES (2) ES2887552T3 (https=)
IL (3) IL262668B2 (https=)
MX (3) MX379016B (https=)
NZ (3) NZ713967A (https=)
PL (1) PL3354277T3 (https=)
RU (2) RU2733466C2 (https=)
WO (1) WO2011017177A1 (https=)
ZA (2) ZA201200704B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
HRP20120994T1 (hr) 2006-02-07 2012-12-31 Shire Human Genetic Therapies, Inc. Stabilizirana smjesa glukocerebrozidaze
AU2009262670B2 (en) 2008-06-26 2013-06-20 Zevra Denmark A/S Use of Hsp70 as a regulator of enzymatic activity
AU2010281403B2 (en) 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
WO2012012461A2 (en) * 2010-07-19 2012-01-26 Shire Human Genetic Therapies, Inc. Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof
CA2817773A1 (en) 2010-11-30 2012-06-07 Orphazyme Aps Methods for increasing intracellular activity of hsp70
US9387236B2 (en) * 2011-06-10 2016-07-12 Prothera Inc. Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
US8609820B2 (en) 2011-10-28 2013-12-17 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
NZ629296A (en) 2012-01-27 2016-06-24 Prothena Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
WO2013130963A1 (en) * 2012-03-02 2013-09-06 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type iii gaucher disease
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
AU2015317447B2 (en) 2014-09-15 2021-02-25 Zevra Denmark A/S Arimoclomol formulation
US20180296542A1 (en) * 2015-09-22 2018-10-18 Saint Louis University Iminosugars for improving bone mineral density in bone disease
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
DK3782624T3 (da) 2016-04-29 2025-12-15 Zevra Denmark As Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
EP3264092A1 (en) * 2016-07-01 2018-01-03 Centogene AG Use of lyso-gb1 as druggable target
CN111278439A (zh) * 2017-10-26 2020-06-12 夏尔人类遗传性治疗公司 包含葡萄糖脑苷脂酶和异烟肼的调配物
US20210113703A1 (en) * 2018-05-27 2021-04-22 Bioasis Technologies Inc. Treatment of gaucher disease
JP7642561B2 (ja) * 2019-04-25 2025-03-10 武田薬品工業株式会社 イソファゴミン塩、その使用方法および製剤
WO2021022045A1 (en) 2019-07-31 2021-02-04 Ecolab Usa Inc. Personal protective equipment free delimer compositions
RU2759054C2 (ru) * 2019-11-27 2021-11-09 федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) Рекомбинантный штамм вируса гриппа A/PR8-NS124-Luc и способ оценки поствакцинальных нейтрализующих антител с использованием биолюминесцентной детекции
EP4139442A4 (en) * 2020-04-23 2024-06-19 Wuxi Biologics Ireland Limited A genetically modified cell line producing a recombinant glycoprotein having a mannose-terminated n-glycan
BR112022026396A2 (pt) * 2020-06-24 2023-03-14 Kempharm Denmark As Arimoclomol para o tratamento da doença de gaucher
CA3188000A1 (en) * 2020-07-13 2022-01-20 Genentech, Inc. Cell-based methods for predicting polypeptide immunogenicity
IL301549A (en) * 2020-10-01 2023-05-01 Sangamo Therapeutics Inc Methods of detecting anti-aav antibodies
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5241093B2 (https=) 1973-05-16 1977-10-17
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5272066A (en) * 1986-03-07 1993-12-21 Massachusetts Institute Of Technology Synthetic method for enhancing glycoprotein stability
WO1989005850A1 (en) 1987-12-23 1989-06-29 The United States Of America, As Represented By Th Cloned dna for synthesizing unique glucocerebrosidase
US5549892A (en) * 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5236838A (en) * 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
JPH03503721A (ja) 1988-12-23 1991-08-22 ジェンザイム　コーポレイション 酵素的に活性な組換えグルコセレブロシダーゼ
WO1990007573A1 (en) 1988-12-23 1990-07-12 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
DE69213714T2 (de) 1991-01-21 1997-01-23 Genzyme Corp., Cambridge, Mass. Herstellung enzymatischer aktiver glukocerebrosidase von rekombinanten zellen
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5911983A (en) 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
DK0675727T3 (da) 1992-12-10 2002-08-05 Enzon Inc Glycolipidenzympolymerkonjugater
WO1994014837A1 (en) 1992-12-21 1994-07-07 Enzon, Inc. Purification of proteinaceous material
EP0675204B1 (en) 1994-03-30 2001-05-30 Takara Shuzo Co. Ltd. Transglycosylating process for producing carbohydrates or glycoconjugates
JP3002113B2 (ja) 1994-03-30 2000-01-24 寳酒造株式会社 糖質又は複合糖質の製造方法
US5670132A (en) 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
DE69637875D1 (de) 1995-09-14 2009-04-30 Virginia Tech Intell Prop Produktion von lysosomalen enzymen in pflanzlichen expressionssystemen
JP2002504083A (ja) 1996-03-05 2002-02-05 オーケスト インコーポレイテッド ヒアルロン酸および増殖因子による骨の増殖を促進する方法
US6177447B1 (en) 1996-07-15 2001-01-23 Universiteit Van Amsterdam Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
JP4001925B2 (ja) 1996-09-13 2007-10-31 トランスカーヨティック セラピーズ インク． α―ガラクトシダーゼＡ欠損症の治療
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
JPH10273500A (ja) 1997-03-03 1998-10-13 Noguchi Inst 複合糖ペプチド及びその製造法
JPH10306099A (ja) 1997-03-04 1998-11-17 Noguchi Inst 新規複合糖ペプチドおよびその製法
TW542721B (en) 1997-08-06 2003-07-21 Melaleuca Inc Dietary supplements containing natural ingredients
US6340746B1 (en) 1997-08-07 2002-01-22 University Of Utah Prodrugs and conjugates of thiol- and selenol- containing compounds and methods of use thereof
US5939279A (en) * 1997-09-18 1999-08-17 The Board Of Trustees Of The University Of Arkansas Inhibition of bacterial binding by high-mannose oligosaccharides
WO1999032135A1 (en) 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
GB9802249D0 (en) 1998-02-03 1998-04-01 Ciba Geigy Ag Organic compounds
GB9807464D0 (en) 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
EP0976838A1 (en) 1998-05-06 2000-02-02 Rhone-Poulenc Nutrition Animale Enzymes mixture
JPH11318441A (ja) 1998-05-14 1999-11-24 Nagase & Co Ltd 超耐熱耐酸性アミロプルラナーゼ
KR19990086271A (ko) 1998-05-27 1999-12-15 손경식 면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제
EP1084240A1 (fr) 1998-06-05 2001-03-21 Aventis Pharma S.A. Polypeptides possedant une activite de type beta-secretase
ES2558160T3 (es) 1998-12-09 2016-02-02 Phyton Holdings, Llc Glicoproteínas que tienen glicosilación de tipo humano
GB9909066D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
WO2000076480A2 (en) * 1999-06-11 2000-12-21 Eli Lilly And Company Pharmaceutical materials and methods for their preparation and use
ATE234626T1 (de) 1999-07-26 2003-04-15 Searle & Co Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin mit glucocerebrosidase enzyme zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
US6537785B1 (en) * 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US6770468B1 (en) * 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
DE60031999T2 (de) 1999-10-04 2007-06-06 Novartis Vaccines and Diagnostics, Inc., Emeryville Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen
AU2352201A (en) 1999-12-30 2001-07-16 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
WO2001097829A2 (en) * 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
CN1156702C (zh) * 2001-07-11 2004-07-07 上海晶泰生物技术有限公司 采用标记链霉亲和素-生物素技术的蛋白质芯片
WO2003048357A1 (fr) 2001-12-04 2003-06-12 Mitsubishi Pharma Corporation Procede d'activation de proteine
AU2003211990A1 (en) 2002-02-14 2003-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
US7429460B2 (en) * 2003-01-15 2008-09-30 Yeda Research And Development Co., Ltd. Methods of screening for inhibitors of phospholipid synthesis related to glycolipid-storage diseases
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
PT2441467E (pt) 2003-01-31 2015-10-12 Sinai School Medicine Terapia combinada para o tratamento de transtornos associados a uma deficiência proteica
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
MXPA06011824A (es) * 2004-04-16 2006-12-15 Genentech Inc Ensayo para anticuerpos.
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
EP1828224B1 (en) 2004-12-22 2016-04-06 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
HRP20120994T1 (hr) 2006-02-07 2012-12-31 Shire Human Genetic Therapies, Inc. Stabilizirana smjesa glukocerebrozidaze
US7713709B2 (en) * 2006-03-17 2010-05-11 Biomarin Pharmaceutical Inc. Assay for detection of antibodies to lysosomal enzymes
EP2012788A4 (en) * 2006-04-18 2010-05-26 Ekr Therapeutics Inc PREPARED USE-READY INTRAVENOUS BOLUSA COMPOSITIONS AND USE METHOD
PT1860101E (pt) 2006-05-24 2011-07-12 Amicus Therapeutics Inc Sal de tartrato da isofagomina e métodos de uso
JP5303458B2 (ja) * 2006-06-23 2013-10-02 アミークス セラピューティックス インコーポレイテッド β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法
DK2041270T3 (da) * 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
TWI489984B (zh) * 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
AU2010281403B2 (en) 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
EP2542674B1 (en) 2010-03-02 2014-01-15 Protalix Ltd. Glucocerebrosidase multimers and uses thereof
WO2012012461A2 (en) 2010-07-19 2012-01-26 Shire Human Genetic Therapies, Inc. Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof

Similar Documents

Publication Publication Date Title
JP2013500976A5 (https=)
CN109172813B (zh) 用于治疗戈谢病的组合物和方法
Powell et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
Pouliquen et al. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab
JP6475293B2 (ja) Ｉｉｉ型ゴーシェ病を治療するための組成物および方法
JP2020530002A (ja) Ｄｌｂｃｌ患者サブグループのオビヌツズマブ治療
JP2022523328A (ja) 治療に対する応答での患者における疾患の進行および退行をモニタリングするための組成物および方法
Singh et al. Thymoma-associated exfoliative dermatitis with post-thymectomy myasthenia gravis in a cat
Volkow et al. Carbon-11-cocaine binding compared at subpharmacological and pharmacological doses: a PET study
Agersø et al. Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients
JP2010519512A5 (https=)
WO2018107205A1 (en) Radiolabelled material for targeted administration
Hirai et al. Imaging alloreactive T cells provides early warning of organ transplant rejection
JP2019523759A5 (https=)
WO2020014175A1 (en) Methods and compositions for analyzing immortalized megakaryocyte progenitor cell lines and platelet-like particles derived therefrom
Mostafa et al. Effect of candesartan and ramipril on liver fibrosis in patients with chronic hepatitis C viral infection: a randomized controlled prospective study
Riviere et al. Bioequivalence of a novel omalizumab solution for injection compared with the standard lyophilized powder formulation
WO2020010189A1 (en) Methods and compositions for analyzing platelets by mass cytometry
Shaw et al. Effect of PCC on thrombin generation among patients on factor Xa inhibitors with major bleeding or needing urgent surgery (GAUGE): design and rationale
Keir et al. Airway responsiveness in an allergic rabbit model
BR112019023141A2 (pt) métodos de tratamento seletivo da asma usando antagonistas de il-17
Fragni Identification of novel readouts to assess anti-fibrotic efficacy of new compounds in a bleomycin-induced pulmonary fibrosis mouse model
US20260116977A1 (en) Methods of treating melanoma using an anti-ctla4 antibody
WINDYGA et al. Disclosure of Interest: None declared.
Patel et al. Antigen-induced bronchial hyperresponsiveness in the rabbit is not dependent on M2-receptor dysfunction